Münci Yağcı

Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

G. Follows, A. Howes, A. Kater, 2023, The Lancet. Oncology.

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

K. Stamatopoulos, D. Lad, T. Chatzikonstantinou, 2023, EClinicalMedicine.